Nov 6, 7:23 AM ET
Sylvamo reported a third-quarter 2026 net loss of $199 million, or $4.98 per diluted share, driven by a $284 million loss from discontinued operations, primarily a noncash impairment tied to its Europe business. Sales from continuing operations of $645 million and adjusted operating earnings of $53 million were both lower than a year earlier but higher than the second quarter. The company also said it entered a put option agreement with Midas Atlantic Partners for a binding offer to acquire its Europe business, which it says would leave Sylvamo more focused on Latin America and North America.
- Net sales from continuing operations were $645 million, versus $662 million in Q3 2025 and $614 million in Q2 2026.
- Net loss was $199 million ($4.98 per diluted share), including a $284 million loss from discontinued operations.
- Adjusted operating earnings were $53 million ($1.33 per diluted share), versus $72 million ($1.79) a year earlier.
- Put option agreement with Midas Atlantic Partners for a binding offer to acquire the Europe business; dividend of $0.45 per share was paid Oct. 16.
Read the filing on SEC.gov ↗
Nov 6, 6:02 AM ET
Sylvamo entered a put option agreement with Midas Atlantic Partners, backed by The Najafi Companies, for a binding offer to acquire its Europe business. The buyer would take the business with an agreed level of working capital and cash, and Sylvamo would receive 20% of future distributions; no purchase price is stated. The company must complete works council and employee consultations before a final decision, and closing is expected by the end of the first quarter of 2027.
- Buyer is Midas Atlantic Partners, in partnership with The Najafi Companies
- Sylvamo would receive 20% of future distributions from the business in exchange for the transfer
- Final decision follows consultations with works councils and employee representatives
- Closing is expected by the end of the first quarter of 2027
Read the filing on SEC.gov ↗
Aug 7, 7:14 AM ET
Sylvamo reported a second-quarter 2026 net loss of $11 million, compared with net income of $15 million a year earlier, while net sales rose to $806 million from $794 million. Adjusted EBITDA fell to $60 million from $82 million, and free cash flow was negative $23 million, so shareholders face weaker profit in the quarter despite higher sales. Management said it expects a much better earnings performance in the second half of 2026.
- Net loss of $11 million, or $0.28 per diluted share, versus net income of $15 million, or $0.37 per share, in Q2 2025
- Net sales of $806 million, up from $794 million a year earlier and $755 million in Q1 2026
- Adjusted EBITDA of $60 million versus $82 million in Q2 2025; free cash flow was negative $23 million
- A $12 million valuation allowance on certain foreign deferred tax assets drove the effective tax rate to 1200%
Read the filing on SEC.gov ↗
May 8, 7:14 AM ET
Sylvamo reported a first-quarter 2026 net loss of $3 million, or $0.08 per diluted share, compared with net income of $27 million a year earlier. Net sales fell to $755 million from $821 million, and adjusted EBITDA dropped to $29 million from $90 million, which the company attributed to a transition year with capacity constraints, lower sales volume and higher costs. The company also declared a $0.45 dividend for the second quarter and did not provide new full-year guidance in the release.
- Net loss of $3 million, or $0.08 per diluted share, versus net income of $27 million, or $0.65 per diluted share, in Q1 2025
- Net sales of $755 million versus $821 million in Q1 2025 and $890 million in Q4 2025
- Adjusted EBITDA of $29 million (4% margin) versus $90 million (11% margin) in Q1 2025; free cash flow was negative $59 million
- Board declared a $0.45 dividend for the second quarter, paid April 28
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.